(NASDAQ: HBIO) Harvard Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 300.7%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,670.09%.
Harvard Bioscience's earnings in 2026 is -$56,700,000.On average, 4 Wall Street analysts forecast HBIO's earnings for 2026 to be $4,333,357, with the lowest HBIO earnings forecast at $2,629,530, and the highest HBIO earnings forecast at $6,104,265.
In 2027, HBIO is forecast to generate $9,122,858 in earnings, with the lowest earnings forecast at $8,765,098 and the highest earnings forecast at $9,391,177.